Drug intelligence / Profile preview

alcohol + placebo

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

This entry refers to a combination of alcohol (ethanol) and placebo, typically used in clinical research settings. Alcohol is a central nervous system depressant that acts primarily by enhancing the effects of γ-aminobutyric acid (GABA) at the GABA~A~ receptor, leading to sedation, impaired cognitive and motor function, euphoria, and other psychoactive effects. Placebo is an inert substance with no pharmacological activity, used as a control in clinical trials to assess the true effect of active substances like alcohol. The combination "alcohol + placebo" is not a therapeutic product but rather denotes an experimental design where subjects receive either alcohol or an inactive comparator for study purposes[2][6][8].

Other names: ALC + placebo

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on alcohol + placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alcohol + placebo.

Explore the full profile